Ultrasound System

The SonoTran® Ultrasound System is a novel proprietary device uniquely designed to effectively image, treat, and monitor target tissue regions in the oncology ward.

Using a purpose-designed handheld ultrasound probe, conventional B-mode imaging can be used to guide treatment to target tissue regions, with the additional capability to register and guide by pre-treatment higher resolution CT or MR. Using the same purpose-designed probe, a treatment mode engages to transmit ultrasound waves at safe, diagnostic-level pressures focused to a user-selectable target region. These focused waves cause the air bubbles contained within SonoTran Sonosensitive Particles to expand and collapse - a phenomena called inertial cavitation.  This in turn causes a fluidic micro-stream which forces a net movement of fluid away from the focus.

The SonoTran Ultrasound System has been designed with clinical input to be used efficiently in an oncology day treatment unit rather than a radiology ward.

The SonoTran Ultrasound System uses patent protected "Passive Acoustic Mapping" algorithms providing a means of real-time treatment monitoring, which can be extended to full 3D treatment monitoring if utilizing CT/MR registration.


text image
text image
the ultrasound system
a sonosensitive particle
Sonosensitive Particles

OxSonics’ proprietary Sonosensitive Particles have been developed to carry pre-formed stabilised gas bubbles to enable sustained levels of inertial cavitation using low (quasi-diagnostic) ultrasound intensities at tumour sites.

The Sonosensitive Particles confer the following enabling features:

  • Optimal Pharmacokinetics

The Particles possess in vivo circulation kinetics compatible with any therapeutic agent and sufficient time to administer ultrasound to the anatomic region of interest.

  • Range of Administration Routes

The Particles are designed to adopt the same administration route as the therapeutic agent, including intravenous (IV), intra-tumoural (IT) or intraperitoneal (IP).

  • Optimal & Consistent Size

The Particles are of a consistent size and have been designed to extravasate via the enlarged endothelial junction gaps exclusively found in solid tumours.

  • Sustained Levels of Cavitation

Due to the number density and physical properties of the Particles, the cavitation process is repeatable and sustained through successive ultrasound pulses. This enables gradual active convection of the therapeutic agent to distances of greater than 200 microns from blood vessels into tumours.

  • No Drug Reformulation

The particles are independently administered alongside the therapeutic agent, no drug reformulation is required.

  • Medical Device Classification

The Particles are classified as medical devices not drugs, conferring a range of regulatory benefits.

  • Clinical Workflow Integration

The particles will be delivered to the patient via an infusion bag and giving set making their administration to the patient fit neatly within current oncology ward clinical practice.


text image

© OxSonics Ltd 2018